NAT1 Genotypes Do not Predict Response to Mesalamine in Patients with Ulcerative Colitis | Zendy

Martin Hausmann | Zendy; Gregor Paul | Zendy; K Menzel | Zendy; R Brunner-Ploss | Zendy; W Falk | Zendy; J Schölmerich | Zendy; H Herfarth | Zendy; Gerhard Rogler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

NAT1 Genotypes Do not Predict Response to Mesalamine in Patients with Ulcerative Colitis

Author(s) -

Martin Hausmann,

Gregor Paul,

K Menzel,

R Brunner-Ploss,

W Falk,

J Schölmerich,

H Herfarth,

Gerhard Rogler

Publication year - 2008

Publication title -

zeitschrift für gastroenterologie

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.316

H-Index - 58

eISSN - 1439-7803

pISSN - 0044-2771

DOI - 10.1055/s-2007-963673

Subject(s) - ulcerative colitis , medicine , genotype , gastroenterology , biology , genetics , disease , gene

5- Aminosalicylic acid (5-ASA) is metabolised in colonic mucosa by N-acetyltransferase 1 (NAT1). Common genetic polymorphisms in this enzyme result in rapid or slow acetylation. 5-ASA treatment causes side effects in up to 10 % of patients with ulcerative colitis (UC). We therefore determined genetic variations of NAT1 in patients with UC and looked for a possible association with the clinical response to 5-ASA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research